Pharvaris N.V. (PHVS) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

52/100

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

32

Expensive

Momentum

84

Strong Up

Sentiment

58

Mixed

Risk resilience

73

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Industry: Biotechnology
Sector: Healthcare
Headquarters: CH
CEO: Berndt Modig
Listed since: Feb 4, 2021
Employees: 148

Market position

Day range

Current $36.41

$35.80$36.4414

52-week range

Current $36.41

$20.65$36.933

Open: $36.27
Previous close: $36.27
Volume: 47.51K; 0.11× average
Average volume: 447.49K; Average daily volume
Market cap: 2.54B USD
Beta: -2.33; Market reference 1
50-day average: $34.0942; +6.79% above average
200-day average: $28.8961; +26.00% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 1.11B EUR
P/E (TTM): -11.56×
P/B (TTM): 7.06×
P/S (TTM): 0×
EV / EBITDA: -6.38×
Earnings yield: -12.57%
Free cash flow yield: -9.82%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: -64.77%
Return on assets: -58.28%
Return on invested capital: -62.42%

Financial health

Debt / equity: 0×
Current ratio: 10.11×
Altman Z-score: 43.29
Piotroski F-score: 2 of 9

Financial statements

Income trends

Operating income

−169.82M EUR-16.57%

Net income

−175.7M EUR-30.90%

Metric (EUR)	FY2025	FY2024	FY2023	FY2022	FY2021
Research and development	124.48M EUR	98.56M EUR	65.58M EUR	57.38M EUR	35.79M EUR
Selling, general, and administrative	45.34M EUR	47.12M EUR	31.34M EUR	29.34M EUR	18.35M EUR
Operating expenses	169.82M EUR	145.69M EUR	96.91M EUR	86.71M EUR	54.14M EUR
Interest income	—	5.47M EUR	—	16.11 EUR	267.51 EUR
Interest expense	—	—	—	16.11K EUR	278.18K EUR
Depreciation and amortization	418.35K EUR	95K EUR	257.55K EUR	152.94K EUR	77.37K EUR
Operating income	−169.82M EUR	−145.69M EUR	−96.91M EUR	−86.71M EUR	−54.14M EUR
Net income	−175.7M EUR	−134.22M EUR	−100.88M EUR	−76.33M EUR	−42.73M EUR

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate: 36%; 4 beats, 7 misses, 0 met estimates
Average EPS surprise: -6.91%; 11 comparable reports
Latest EPS result: -0.81; Estimate -0.75 · Miss by 8.48%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$52.71

44.77% upside

Past 12 months12-month forecastHigh $74.00Average $52.71Low $40.00

Rating distribution

12 ratings

Strong buy00%

Buy1192%

Hold18%

Sell00%

Strong sell00%

Recent analyst actions

11 institutions

PHVS news

globenewswire.comAug 12, 2026

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

ZUG, Switzerland, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living…

Read source

globenewswire.comAug 6, 2026

Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology

ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living…

Read source

seekingalpha.comAug 4, 2026

Pharvaris: One Molecule Could Reshape Both Sides Of HAE Treatment

Pharvaris is positioned to build a vertically integrated HAE franchise with deucrictibant in both immediate-release (IR) and extended-release (XR) forms. PHVS's NDA for deucrictibant IR was accepted by the FDA, with a…

Read source

zacks.comJul 31, 2026

Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet

The consensus price target hints at a 43% upside potential for Pharvaris (PHVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean…

Read source

fool.comJul 24, 2026

After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over?

This late-stage biotech innovator in rare disease therapies reported significant insider selling amid strong one-year share price gains.

Read source

globenewswire.comJul 22, 2026

Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema

ZUG, Switzerland, July 22, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living…

Read source